Form 4: Director James E. Shmerling Acquires Stock Options in Harvard Apparatus Regenerative Technology, Inc.
SEC Form 4
James E. Shmerling, a director of Harvard Apparatus Regenerative Technology, Inc., acquired stock options as part of his compensation.
Summary
- On June 27, 2024, James E. Shmerling, a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), was granted two stock option awards.
- The first stock option is for 10,204 shares at an exercise price of $2.92, vesting in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025, and June 27, 2025, and expiring on June 27, 2034.
- The second stock option is for 8,215 shares at an exercise price of $2.92, vesting in four equal installments on June 27, 2024, June 30, 2024, September 30, 2024, and December 31, 2024, and expiring on June 27, 2034.
- This second grant was in lieu of cash compensation.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine director compensation disclosure. The stock options align director interests with shareholders, but the impact is not immediately significant.
Positives
- The grants of stock options to a director align his interests with those of shareholders.
- Part of the compensation is in lieu of cash, which may conserve company cash resources.
Industry Context
Stock option grants are a common form of compensation for directors, especially in smaller companies, to align their interests with shareholders and conserve cash.
Comparison to Industry Standards
- Director compensation packages vary widely across industries and company sizes.
- Stock options are a typical component, often vesting over several years to incentivize long-term commitment.
- The specific number of options and exercise price would need to be compared to similar companies in the regenerative medicine or biotechnology sectors to assess its competitiveness.
Stakeholder Impact
- Shareholders may view the stock option grants positively as they align the director's interests with the company's long-term success.
- The director benefits from the potential upside of the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of stock option grants |
| 06/27/2034 | Expiration date of both stock option grants |
| 07/15/2024 | Date of Form 4 filing |
| 09/27/2024 | First vesting date for the 10,204 share stock option grant |
| 12/27/2024 | Second vesting date for the 10,204 share stock option grant |
| 03/27/2025 | Third vesting date for the 10,204 share stock option grant |
| 06/27/2025 | Fourth vesting date for the 10,204 share stock option grant |
| 06/30/2024 | Second vesting date for the 8,215 share stock option grant |
| 09/30/2024 | Third vesting date for the 8,215 share stock option grant |
| 12/31/2024 | Fourth vesting date for the 8,215 share stock option grant |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.